[Expression of NOV and BNIP3 gene in mouse myelomonocytic leukemia and its significance]
Related Experiment Video
Updated: Jun 2, 2026
Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
Published on: February 21, 2018
Hong-Li Zuo1, En-Lan Peng, Hong-Xia Zhao
1Department of Hematology, Academy of Military Medical Sciences, Beijing 100071, China.
Abstract:
This study was aimed to investigate the expression level of NOV and BNIP3 mRNA in mice myelomonocytic leukemia (AML-M(4)) and its significance. The mice were inoculated intravenously with myelomonocytic leukemia cells of WEHI-3, and divided randomly into chemotherapy group and control (untreated) group. Bone marrow samples were then collected from both groups at different times. The NOV and BNIP3 mRNA expression were detected by TaqMan quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR), and the relationship between these expression levels and clinical significance in leukemia incidence and progression were analyzed with β-actin as the housekeeping gene. The results showed that the mean values of NOV and BNIP3 increased gradually from 2 weeks after inoculation and achieved highest level at death in control group. Expression level of NOV increased from 1.85E-05 before inoculation to 3.57E-02 at death (p < 0.05), and BNIP3 from 3.44E-03 to 3.48E-02. While 2 gene expression in the chemotherapy group decreased quickly to 2.51E-05 and 1.58E-03 (p < 0.05) respectively after chemotherapy, which were close to the level before inoculation (p > 0.05). The 2 gene expressions again rose at relapse, and difference of expression level between 2 group at death were no statistically significant (p > 0.05). It is concluded that the expression of NOV and BNIP3 in leukemia AML-M(4) is significantly higher than that in normal controls, of which high level expression is an important factor in the development of leukemia. Close relation between the therapeutic effect and expression level of these two genes suggests the great value in prognostic evaluation and MRD detection.
Insights
High expression of NOV and BNIP3 mRNA indicates a higher risk and progression in acute myeloid leukemia (AML-M4) in mice. These gene levels correlate with treatment effectiveness, suggesting their value in prognosis and minimal residual disease detection.
Area of Science:
- Molecular Biology
- Oncology
- Biochemistry
Background:
- Acute myeloid leukemia (AML-M4) is a significant hematological malignancy.
- Understanding the molecular mechanisms underlying AML progression is crucial for developing effective therapies.
- NOV and BNIP3 are genes whose roles in AML-M4 require further elucidation.
Purpose of the Study:
- To investigate the mRNA expression levels of NOV and BNIP3 in a mouse model of AML-M4.
- To determine the clinical significance of NOV and BNIP3 expression in leukemia incidence and progression.
- To evaluate the correlation between NOV and BNIP3 expression and the efficacy of chemotherapy.
Main Methods:
- A mouse model of AML-M4 was established using WEHI-3 leukemia cells.
- Mice were divided into chemotherapy and control groups.
- Bone marrow samples were analyzed using TaqMan quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) to measure NOV and BNIP3 mRNA expression, with β-actin as the housekeeping gene.
Main Results:
- NOV and BNIP3 mRNA levels significantly increased in the control group, peaking at the time of death.
- Chemotherapy treatment led to a rapid decrease in NOV and BNIP3 mRNA expression, approaching pre-inoculation levels.
- Relapse was associated with a மீண்டும் rise in the expression of these genes.
Conclusions:
- Elevated NOV and BNIP3 mRNA expression is significantly associated with AML-M4 development and progression in mice.
- High expression levels of NOV and BNIP3 are important factors in leukemia development.
- The correlation between therapeutic effects and NOV/BNIP3 expression highlights their potential value in prognostic evaluation and minimal residual disease detection.
More Related Videos
08:00A Detailed Protocol for Characterizing the Murine C1498 Cell Line and its Associated Leukemia Mouse Model
Published on: October 14, 2016
05:32Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
Published on: January 7, 2019